RxDoctor Payments DataLook up a doctor →

Robert Gardner, MD

Neurology · Cape Girardeau, MONPI 1649365917

Payments from drug & device makers

$171,227in general payments, 2019–2025

Across 1,184 payments — averaging $144.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$101K
  • Amgen$36K
  • Biohaven Pharmaceuticals, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Johnson & Johnson$2K
  • Jazz Pharmaceuticals Inc.$2K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)272$101,297
Amgen102$36,071
Biohaven Pharmaceuticals, Inc.21$11,933
Biohaven Pharmaceutical Holding Company Ltd.12$2,772
Johnson & Johnson(2 entities)35$1,951
Jazz Pharmaceuticals Inc.38$1,723
Novartis118$1,642
Biogen53$1,019
Eisai Inc.26$965
AstraZeneca(2 entities)28$916
Greenwich Biosciences, Inc.34$840
Supernus Pharmaceuticals, Inc.45$709
Teva Pharmaceuticals USA, Inc.43$682
Harmony Biosciences LLC27$635
Lilly USA, LLC18$530
UCB, Inc.23$496
Genentech USA, Inc.21$459
Sanofi14$456
SK Life Science, Inc.15$437
Pfizer23$392
CSL Behring14$358
Sunovion Pharmaceuticals Inc.3$339
Bristol Myers Squibb9$332
TG Therapeutics, Inc.8$330
Amneal Pharmaceuticals LLC14$300
Avadel CNS Pharmaceuticals, LLC6$282
Ipsen Biopharmaceuticals, Inc13$258
Neurocrine Biosciences, Inc.7$238
Argenx US, Inc.8$234
E.r. Squibb & Sons, L.L.C.2$225
Lundbeck LLC12$218
Otsuka America Pharmaceutical, Inc.5$188
Neurelis, Inc.10$186
EMD Serono, Inc.5$164
Acorda Therapeutics, Inc9$129
Acadia Pharmaceuticals Inc7$123
Medtronic3$119
Bausch Health US, LLC13$115
Impel Pharmaceuticals Inc.4$112
Axsome Therapeutics, Inc.6$111
Octapharma USA, Inc.2$74
Adamas Pharmaceuticals, Inc.4$73
Grifols USA, LLC4$71
Akcea Therapeutics, Inc.3$69
GE HealthCare2$67
MDD US Operations, LLC1$67
Catalyst Pharmaceuticals, Inc.3$62
Corium, LLC15$60
Avion Pharmaceuticals3$47
Mallinckrodt Hospital Products Inc.2$40
Vanda Pharmaceuticals Inc.2$33
Upsher-smith Laboratories LLC2$33
Xeris Pharmaceuticals, Inc.2$30
Promius Pharma LLC2$28
Avanir Pharmaceuticals, Inc.2$27
Cala Health, Inc.1$23
Abbott1$23
Hospira, Inc.1$18
Sumitomo Pharma America, Inc.1$18
Tanabe Pharma America, Inc.1$17

How this compares

$171,227 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$372,729
Medicare patients
539
Services billed
39,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Cape Girardeau

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →